\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
HOUSTON, Aug. 2, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company introducing treatments for cancer patients requiring new remedy options, and VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, today announced the signing of a study and progression collaboration to advance immediate epigenetic profiling using Volition’s Nu. Q® generation to aid the progression of Salarius’ clinical-stage drug, seclidemstat.
Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is recently in phase 1/2 clinical studies for hematologic and sham cancers where LSD1 is involved in disease progression. Nu. Q® evolved as simple, easy-to-use cost-effective blood tests to diagnose and monitor a variety of life-changing diseases, including cancer in humans and animals.
“We are excited to collaborate with Volition and its Nu. Q® generation can provide valuable insights into biomarkers as we seek to advance the progression of seclidemstat across multiple clinical indications,” said David Arthur, CEO of Salarius. “Biomarkers enable a non-invasive analysis approach to uncover target compromise and potential drug activity in patients. Therefore, this exciting study collaboration with Volition Rx Limited provides another tool to aid in the progression of seclidemstat in the clinic.
Gael Forterre, Commercial Director of Volition, added: “We are very pleased to collaborate with Salarius on our Nu. Q® Discover program, which provides biopharmaceutical corporations and universities with access to our tests for immediate epigenetic analysis. We look forward to supporting Salarius in the progression and commercialization of its revolutionary seclidemstat treatment, to gain direct advantages from cancer patients.
About VolitionRxVolitionRx Limited is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to expand simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a variety of life-changing diseases, including certain cancers and diseases. related to NETosis such as sepsis and COVID-19. Early diagnosis and follow-up have the perspective not only of prolonging the life of patients but also of their quality of life. The tests are based on nucleosome science, which involves identifying and measuring nucleosomes in blood or other physical fluids to imply the presence of a disease. Volition basically focuses on human diagnosis and monitoring, but also has a subsidiary aimed at animal diagnosis and monitoring.
Volition’s studies and progression activities focus on Belgium, with an innovation lab and on the United States and more in London and Singapore. For more information, visit the Volition Rx Limited website.
About Salarius PharmaceuticalsSalarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer patients in need of new treatment options. Salarius’ product portfolio includes seclidemstat, Salarius’ lead candidate, which is being studied as a potential remedy for pediatric cancers, sarcomas, and other cancers with limited remedial options, and SP-3164, an oral protein-degrading molecule little. Seclidemstat is recently in a phase 1/2 clinical trial for relapsed/refractory Ewing’s sarcoma and other sarcomas that have similar biology, also called Ewing-related or TEF-rearranged sarcomas. Seclidemstat has earned rare pediatric disease, orphan drug, and accelerated designations for Ewing’s sarcoma from the US Food and Drug Administration. Salarius is also exploring the potential of seclidemstat in several cancer types with the greatest unmet medical need, with an investigator-initiated phase 1/2 clinical study in hematologic cancers underway at MD Anderson Cancer Center. Salarius won grant funding from the National Pediatric Cancer Foundation to advance the Ewing Sarcoma clinical program and won a product progression award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, stop by salariuspharma. com or stay with Salarius on Twitter and LinkedIn.
Salarius Forward-Looking Statements This news release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, except statements of past fact, included in this news release are forward-looking statements. These forward-looking statements may be known by terms such as “believe”, “in progress”, “possibly”, “potential”, “progress”, “potential” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding the following: the price and benefits of running Volition Rx; the ability to use biomarkers to advance Salarius product candidates; Salarius growth strategy; the price of seclidemstat as a remedy for Ewing’s sarcoma, Ewing-like sarcomas, and other cancers; expand the scope of Salarius studies and focus on patient populations with the greatest unmet needs; milestones from existing and long-term clinical trials of Salarius, adding the time of data readings. Salarius may not actually achieve the plans, achieve the objectives or meet the expectations or objectives disclosed in the forward-looking statements. You deserve not to place undue reliance on such forward-looking statements. These statements are subject to dangers and uncertainties that may also cause actual effects and functionality to differ materially from those discussed in the forward-looking statements. These dangers and uncertainties include, among others, the following: the adequacy of Salarius’s capital resources; Salarius’ ability and desire to raise additional capital to meet Salarius’ business operating wishes and to achieve its business objectives and strategy; effects of long-term clinical trials and the effect of the effects on Salarius; that the effects of clinical studies and trials may not be predictive of the long-term effects of clinical trials; dangers similar to drug progression and the regulatory approval process; the competitive landscape and other dangers in the industry; and other perils described in Salarius’ filings with the Securities and Exchange Commission, adding its annual report on Form 10-K for the fiscal year ended December 31, 2021, revised or supplemented through its quarterly reports on the Form 10-Q and other documents filed with the SEC. Forward-looking statements in this news release speak only as of the date of this news release and are based on management’s assumptions and estimates as of that date. Salarius disclaims any legal purpose or responsibility to update those forward-looking statements to reflect events or events that exist after the date they are made.
CONTACTS:
For SalariusLHA Investor RelationsKim Sutton Golodetz kgolodetz@lhai. com212-838-3777
For VolitionLouise Batchelor/Debra Daglish mediarelations@volition. com (0)7557 774620